Literature DB >> 17173224

A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec.

Bruno Hubert1, Vivian G Loo, Anne-Marie Bourgault, Louise Poirier, André Dascal, Elise Fortin, Marc Dionne, Manon Lorange.   

Abstract

BACKGROUND: An increase in the incidence and severity of Clostridium difficile-associated disease in Québec and the United States has been associated with a hypervirulent strain referred to as North American pulsed-field type 1 (NAP1)/027.
METHODS: In 2005, a prospective study was conducted in 88 Québec hospitals, and 478 consecutive nosocomial isolates of C. difficile were obtained. The isolates were subjected to pulsed-field gel electrophoresis (PFGE) typing, antimicrobial susceptibility testing, and detection of binary toxin genes and tcdC gene deletion. Data on patient age and occurrence of complications were collected.
RESULTS: PFGE typing of 478 isolates of C. difficile yielded 61 PFGE profiles. Pulsovars A (57%), B (10%), and B1 (8%) were predominant. The PFGE profile of pulsovar A was identical to that of strain NAP1. It showed 67% relatedness with 15 other PFGE patterns, among which 11 had both binary toxin genes and a partial tcdC deletion but different antibiotic susceptibility profiles. Pulsovars B and B1 were identical to strain NAP2/ribotype 001. In hospitals showing a predominant clonal A or B-B1 PFGE pattern, incidence of C. difficile-associated disease was 2 and 1.3 times higher, respectively, than in hospitals without any predominant clonal PFGE pattern. Severe disease was twice as frequent among patients with strains possessing binary toxin genes and tcdC deletion than among patients with strains lacking these virulence factors.
CONCLUSIONS: This study helped to quantify the impact of strain NAP1 on the incidence and severity of C. difficile-associated disease in Québec in 2005. The identification of the geographic dissemination of this predominant strain may help to focus regional infection-control efforts.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17173224     DOI: 10.1086/510391

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  72 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

2.  Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency.

Authors:  J H Boone; M Goodykoontz; S J Rhodes; K Price; J Smith; K N Gearhart; R J Carman; T M Kerkering; T D Wilkins; D M Lyerly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-14       Impact factor: 3.267

3.  Hospital-acquired Clostridium difficile infection: determinants for severe disease.

Authors:  J M Wenisch; D Schmid; H-W Kuo; E Simons; F Allerberger; V Michl; P Tesik; G Tucek; C Wenisch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-31       Impact factor: 3.267

4.  Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1.

Authors:  Thomas Akerlund; Ingela Persson; Magnus Unemo; Torbjörn Norén; Bo Svenungsson; Marlene Wullt; Lars G Burman
Journal:  J Clin Microbiol       Date:  2008-02-20       Impact factor: 5.948

5.  Genotypic investigation of Clostridium difficile in Prince Edward Island.

Authors:  H Martin; L P Abbott; D E Low; B Willey; M Mulvey; J Scott Weese
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-11       Impact factor: 2.471

6.  Use administrative databases with caution.

Authors:  Bruno Hubert; Rodica Gilca
Journal:  CMAJ       Date:  2009-01-06       Impact factor: 8.262

7.  Is fidaxomicin worth the cost? An economic analysis.

Authors:  Sarah M Bartsch; Craig A Umscheid; Neil Fishman; Bruce Y Lee
Journal:  Clin Infect Dis       Date:  2013-05-23       Impact factor: 9.079

8.  Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples.

Authors:  Paul D Stamper; Romina Alcabasa; Deborah Aird; Wisal Babiker; Jennifer Wehrlin; Ijeoma Ikpeama; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2008-12-10       Impact factor: 5.948

9.  Epidemiology of Clostridium difficile-associated disease at University Hospital Basel including molecular characterisation of the isolates 2006-2007.

Authors:  L Fenner; R Frei; M Gregory; M Dangel; A Stranden; A F Widmer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-17       Impact factor: 3.267

10.  Emerging Insights into Antibiotic-Associated Diarrhea and Clostridium difficile Infection through the Lens of Microbial Ecology.

Authors:  Seth T Walk; Vincent B Young
Journal:  Interdiscip Perspect Infect Dis       Date:  2008-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.